Background: As of 2004, the European Pharmacopoeia demands that plasma pools for production of anti-D immunoglobulin should not contain more than 104 IU per mL of parvovirus B19 (B19V) DNA. Hence, before pooling, highly viremic donations have to be identified, and after pooling the level of B19V DNA must be determined. The performance of a new real-time B19V DNA PCR test (Roche, Mannheim, Germany) was studied, using a DNA extractor (NucliSens, bioMerieux, Boxtel, the Netherlands) for isolation of nucleic acid, and using a DNA quantification test (LightCycler apparatus, Roche, Mannheim, Germany) for amplification and detection.
Study Design And Methods: Dilutions of the international B19V DNA standard and reference preparations were tested to determine the precision, linear range, and accuracy of the assay and to calculate the factor for conversion of B19V DNA copies to IUs. The internal control signals, invalid test results, and the effect of cryo-poor plasma were studied as a measure for robustness. Routine performance was assessed by testing 164 manufacturing pools (not screened for B19V) and 1048 test pools of 480 donations each.
Results: The copies-to-IU conversion factor was calculated to be 3.34 (95% CI, 3.07-3.63). The assay appears linear between 10(3) and 10(7) IU per mL. Between 10(3) and 10(5) IU per mL, the test can discriminate samples differing a factor two in B19V DNA content. Overall, 0.78 percent of the test results were invalid. Of 127 B19V DNA negative control plasma samples, 7 were contaminated with low levels of B19V DNA. Of 164 nonscreened manufacturing plasma pools, 92 contained B19V DNA (56%); 13 contained more than 10(4) IU per mL. Of 503,040 donations, 29 contained more than 5 x 10(6) IU per mL B19V DNA (1:17,346).
Conclusion: The B19V DNA quantification test (LightCycler, Roche ) is suitable for quantitative, routine, in-process measurement of B19V DNA levels in plasma pools, using the DNA extractor (NucliSens, bioMerieux) for nucleic acid isolation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.0041-1132.2004.00610.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HHV-6B, HHV-7, and B19V Are Frequently Found DNA Viruses in the Human Thymus but Show No Definitive Link with Myasthenia Gravis.
J Infect Dis
December 2024
Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Myasthenia gravis (MG) is a rare autoimmune disorder characterised by muscle weakness resulting from autoantibody-mediated disruption of the neuromuscular junction. Notably, it is also frequently associated with thymic pathology. This study explores the relationship between MG and DNA viruses in the thymus, employing targeted NGS and qPCR to analyse thymic tissue samples from both MG patients and healthy controls.
View Article and Find Full Text PDF[Seroprevalence and infection by human parvovirus B19 in pregnant women from Córdoba, Argentina, 2021-2022].
Rev Fac Cien Med Univ Nac Cordoba
December 2024
Universidad Nacional de Córdoba.
Introduction: parvovirus B19 (B19V) infection during pregnancy can be transmitted to the fetus and cause serious complications such as fetal hydrops and stillbirth. The preexistence of specific IgG prevents vertical transmission. Seroprevalence in fertile age is variable (50-70%) and depends on the region/viral circulation, in addition to factors such as maternal age and frequent exposure to children.
View Article and Find Full Text PDFGATA1 transcription factor targets the gene expression of B19 virus in HEK293 cell line.
Ann Med Surg (Lond)
December 2024
Department of Laboratory Hematology and Blood Banking, Dezful University of Medical Sciences, Iran.
Background/aim: B19 virus (B19V) is a single-strand DNA virus that has specific tropism to erythroid progenitor cells (EPCs). The virus enters the cells via P antigen and coreceptors and induces infection and cell apoptosis. GATA1 has a high expression in EPC and is a critical transcription factor for the cells development and differentiation.
View Article and Find Full Text PDFA DNA sensor based on CbAgo effector protein and on a dual electrochemical signal amplification strategy for B19 parvovirus detection.
Bioelectrochemistry
April 2025
Hubei Province Key Laboratory of Occupational Hazard Identification and Control, School of Public Health, Faculty of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China. Electronic address:
Human parvovirus B19 is a prevalent childhood infectious virus that poses a great challenge to public health, so the detection of B19V is of great importance. In this study, a DNA sensor based on CbAgo, a Cas effector, and a dual electrochemical signal amplification strategy was developed by using a novel nanocomposite MnO/CMK-3/g-CN/AgNPs for initial signal amplification, with CMK being an ordered mesoporous carbon nanomaterial. Single-walled carbon nanotubes (SWCNTs) were used as electrocatalytic probes for secondary signal amplification to detect B19 DNA.
View Article and Find Full Text PDFHuman parvovirus B19 vertical infection and hydrops fetalis. A case report.
Arch Argent Pediatr
October 2024
Instituto de Virología Dr. J. M. Vanella, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
Article Synopsis
- * A case is presented where a 30-year-old mother with anemia and hydrops fetalis delivered a preterm baby, but initial maternal testing for B19V was misleading, showing only IgG and no IgM.
- * Ultimately, postnatal testing confirmed B19V infection in the newborn, highlighting the need for updated screening protocols that include early molecular tests to better diagnose and manage congenital infections.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!